AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03920241 — intervention group
Intervention type: BEHAVIORAL
Intervention: Compassion Cultivation Training
Description: The CCT is an 8-week standardized program (Jinpa, 2010; Jazaieri et al. 2013, 2014) consisting of 2.5-hour of face-to-face weekly sessions and 30 minutes of daily home formal and informal practices. Training will be conducted in groups of 20-30 participants. The CCT consists of six sequential steps: 1) Settling the mind and learn how to focus it; 2) Loving kindness and compassion for a loved one practice; 3) Loving kindness and compassion for oneself practice; 4) compassion toward others, embracing shared common humanity and developing appreciation of others; 5) compassion toward others including all beings; and 6) active compassion practices (Tonglen) which involve explicit evocation of the altruistic wish to do something about others' suffering.~CCT program is delivered by certificated instructors by the University of Stanford Centre for Compassion and Altruism Research and Education (http://ccare.stanford.edu/).
Study NCT03920241 — intervention group
Intervention type: OTHER
Intervention: Control Group
Description: A group of participants, matched by age, gender, and meditation experience is selected to compare their performance on experimental lab tasks in relation to the MBSR and CCT participants.
Study NCT04115124 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Participatory Action Research
Description: The research will employ a Participatory Action research quasi-experimental pre-post test study design .
Study NCT04005495 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teaching kitchen program
Description: The teaching kitchen program will include five 4-hour Saturday classes every other weekend over the course of 10 weeks (5 sessions totaling 20 hours of instruction). It will be taught by subject matter experts from the Emory University faculty and staff as well as potentially from the community. The classes will include the scientific rationale, practical applications, and recommendations for implementing self-care components into participants' daily lives. Experiential learning will include hands-on cooking demonstrations, mindfulness-based lunches, a yoga session, and a group exercise session. Rather than being prescriptive, the lectures and demonstrations are geared to inspire self-designed and personalized alterations in dietary patterns and behaviors that will match participants' culture, preferences, and health conditions. Biometrics and survey instruments will be assessed at 4 times: at baseline, after the 10-week program, and at 6 and 12 months after the program.
Study NCT02487160 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SBL-3 multifocal intraocular lens
Description: The SBL-3 intraocular lens will be implanted after the cataractous natural lens has been removed, in those patients randomized into this group
Study NCT02487160 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control monofocal intraocular lens
Description: The Control intraocular lens will be implanted after the cataractous natural lens has been removed, in those patients randomized into this group
Study NCT00295646 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tamoxifen
Description: 20 mg/d
Study NCT00295646 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: anastrozole
Description: 1 mg/d
Study NCT00295646 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: zoledronic acid
Description: 4 mg q6m
Study NCT00295646 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: goserelin
Description: 3.6 mg goserelin subcutaneously every 28 days
Study NCT02441101 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RV DDD(R)-60 with AV optimization
Description: Device to be programmed for RV pacing with AV interval optimization at the bedside to produce QRS fusion with the native conduction down the native left bundle on surface EKG
Study NCT02441101 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: RV DDD(R)-60
Description: AV settings programmed to minimize RV pacing - standard demand pacing programming.
Study NCT02075086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xelox or Xeliri Bevacizumab
Description: Chemotherapy treatment
Study NCT04875494 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Counseling/support group therapy
Description: 6 weeks of counseling group therapy; 2 sessions of 30 min each week, with a psychologist and two former victims
Study NCT04875494 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Exercise
Description: 6 weeks of physical exercise training; 2 sessions of 30 min each week, with an instructor
Study NCT01603043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Al-78898A
Description: 0.400 milligrams (mg) per 50 microliters (μL) administered as an intravitreal injection
Study NCT01603043 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham injection
Description: Mock injection administered as an empty hub without needle
Study NCT02043145 — intervention group
Intervention type: BIOLOGICAL
Intervention: botulinum toxin Type A
Description: Botulinum toxin Type A (BOTOX®) as prescribed according to standard of care in clinical practice.
Study NCT01720303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: repaglinide
Description: 2 mg (tablets) before each main meal
Study NCT01720303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isophane human insulin
Description: Injection s.c. (under the skin) at bedtime
Study NCT01720303 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin
Description: Injection s.c. (under the skin) twice daily
Study NCT01055613 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vistakon Investigational Multi-Purpose Solution I
Description: Multi-purpose contact lens care solution.
Study NCT01055613 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ReNu MultiPlus Multi-Purpose Solution
Description: Multi-purpose contact lens care solution
Study NCT04379453 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robot Assisted Percutaneous Cardiovascular Intervention
Description: Robot Assisted Percutaneous Cardiovascular Intervention
Study NCT03463837 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment with JUUL 5%, Virginia Tobacco
Description: JUUL 5%, ENDS for 5-days in confinement
Study NCT03463837 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment with JUUL 5%, Cool Mint, ENDS
Description: JUUL 5%, ENDS for 5-days in confinement
Study NCT03463837 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment with JUUL 5%, Mango, ENDS
Description: JUUL 5%, ENDS for 5-days in confinement
Study NCT03463837 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: JUUL 5%, Creme Bruele, ENDS
Description: JUUL 5%, ENDS for 5-days in confinement
Study NCT03463837 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Combustible cigarette
Description: Exclusive use of combustible cigarette for 5 days in confinement.
Study NCT03463837 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Smoking Cessation
Description: No smoking for 5-days in confinement.
Study NCT00755807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine Hydrochloride (HCI)
Description: Participants received 30 mg duloxetine (po, QD) for 1 week followed by 5 weeks at 60 mg in the acute placebo-controlled period. If the participant completes the double-blind portion of the trial, the participant will be offered the option to participate in the open-label extension period (given 60, 90, or 120 mg QD for 12 weeks).
Study NCT00755807 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants received placebo oral (po), once daily (QD) for 6 weeks (acute phase). If the participant completes the 6-week double-blind portion of the trial, the participant will be offered the option to participate in the open-label extension period (given 60, 90, or 120 milligrams \[mg\] QD for 12 weeks).
Study NCT00736112 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food Allergy Testing
Description: Food Allergy Diagnosis - blood drawn for food allergy testing at the time of surgery (bilateral myringotomy with tympanostomy tubes +/- adenoidectomy)
Study NCT02872675 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HOST-DM059
Description: Experimental Supplement: HOST-DM059.~Participants will be asked to orally consume one powdered sachet each day, at the same time in the morning, reconstituted in tea/coffee/fruit juice, or sprinkled over cereal etc. Whichever method of consumption is chosen, this must be kept consistent across both supplementation phases.
Study NCT02872675 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Placebo Comparator: Maltodextrin.
Study NCT03062813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus &entecavir
Description: HBV-GN patients with nephrotic syndrome were randomly givenTacrolimus (0.05-0.1 mg/kg/day) combined with entecavir. Tacrolimus was divided into two daily doses at 12-hour intervals. Subsequent doses were adjusted to achieve a whole blood 12-hour trough level between 5 and 10 ng/ml.All patients will receive entecavir antiviral therapy(0.5mg/d), entecavir was taken once a day. All of HBV-GN patients were followed up to 25week.
Study NCT03062813 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo & entecavir
Description: HBV-GN patients with nephrotic syndrome were randomly givenTacrolimus placebo (0.05-0.1 mg/kg/day) combined with entecavir.Tacrolimus placebo was divided into two daily doses at 12-hour intervals. All patients will receive entecavir antiviral therapy(0.5mg/d), entecavir was taken once a day. All of HBV-GN patients were followed up to 25week.
Study NCT03268213 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbial Transplantation
Description: Fecal microbial transplant is offered as treatment option to eligible patients. Donors selected by the patients will be screened by questionnaire and by blood and stool tests for potential transmissible pathogens.~The stool filtrate will be administered in the ileum and/or cecum via colonoscopy
Study NCT03752151 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MARVEL 2 Algorithm Monitor Mode then Adaptive Mode
Description: Software download into implanted Micra device and programmed to MARVEL 2 Monitor Mode then MARVEL 2 Adaptive Mode
Study NCT00998881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teneligliptin 20 mg
Study NCT00998881 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03803748 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eyestil Plus®
Description: • To demonstrate the non-inferiority of Eyestil Plus® compared to Vismed Multi® in terms of clinical performance as detected by a reduction of keratitis lesions objectified by staining tests after 1 month of treatment, in patients with moderate to severe dry eye syndrome with keratoconjunctivitis
Study NCT02292329 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Acai puree, frozen blended it with banana
Description: 150g of acai fruit, frozen blended it with banana.
Study NCT02292329 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control Macronutrient matched
Description: Macronutrient matched control in water and also prepared with banana.
Study NCT00586222 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 Fatty Acid
Description: 600 mg of eicosapentaenoic acid, 340 g of docosahexanoic acid, and 96 mg gama-linoleic acid for 12 weeks.
Study NCT02992301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab
Description: Injectable prescription medicine called a PCSK9 inhibitor.
Study NCT04117399 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary rehabilitation
Description: The experimental group receives inspiratory muscle training and aerobic exercise. The Active Comparator group received only aerobic exercise group received only aerobic exercise.
Study NCT04117399 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation
Description: The experimental group receives inspiratory muscle training and aerobic exercise. The Active Comparator group received only aerobic exercise group received only aerobic exercise.
Study NCT02253641 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Weight Loss Intervention
Description: 14-session/6-month standard behavioral weight loss intervention
Study NCT02253641 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress-Focused Weight Loss Intervention
Description: 14-session/6-month tailored behavioral weight loss intervention
Study NCT04447534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine or hydroxychloroquine
Description: Chloroquine or hydroxychloroquine
Study NCT04447534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zinc
Description: Zinc tablets
Study NCT06376838 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DLMR01
Description: Experimental and Acitve Comparator are applied 1 time to each of crow's feet on both sides of the subject.
Study NCT06376838 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rejuran
Description: Experimental and Acitve Comparator are applied 1 time to each of crow's feet on both sides of the subject.
Study NCT04265898 — intervention group
Intervention type: DEVICE
Intervention: The Digital Virginia Tech Carilion Cognitive Examination
Description: Completion of a newly developed digital cognitive screen
Study NCT02186457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polymyxin B in Normal Saline
Description: Antibiotic irrigation via peritoneal lavage
Study NCT00393029 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: 720,000 IU/kg intravenously over 15 minutes every 8 hours for up to 5 days
Study NCT00393029 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Beginning on day 1 or 2, administered subcutaneously at a dose of 5 mcg/kg/day (not to exceed 300 mcg/day); continue daily until neutrophil count > 1.0 x 10\^9/L x 3 days or > 5.0 x 10\^9/L.
Study NCT02186457 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: Normal Saline
Description: Placebo irrigation via peritoneal lavage
Study NCT01522443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cabozantinib
Description: Tablets taken orally once daily.
Study NCT01522443 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mitoxantrone
Description: Given by IV once every 3 weeks.
Study NCT01522443 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Description: Taken twice a day orally by mouth. Commercially-obtained prednisone tablets will be over-encapsulated in order to blind identity.
Study NCT00569621 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: physiological saline
Description: intravenous administration
Study NCT03627507 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepa-B
Description: Incepta will manufacture a locally produced Hepatitis B vaccine named 'Hepa- B' which contain recombinant Hepatitis B surface antigen obtaine. This bulk is formulated to prepare finished dosage to manufacture large scale in fully GMP compliant plant. Incepta has conducted preclinical study at Bioneed, India. After successful completion of preclinical study, this non inferiority clinical trial with innovator product is needed for Licensure in Bangladesh.
Study NCT03627507 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix B
Description: .'Engerix B' is a recombinant DNA hepatitis B vaccine. It is sterile suspension of purified surface antigen of hepatitis B virus obtained by culturing genetically yeast cells (Saccharomyces cerevisiae cells), which carry the gene that codes for HBsAg
Study NCT03098914 — intervention group
Intervention type: OTHER
Intervention: Cohort Study； pathogen； clinical features
Description: Cohort Study； pathogen； clinical features
Study NCT01307553 — intervention group
Intervention type: DEVICE
Intervention: Pericardium Covered Stent
Description: Percutaneous implantation of pericardium covered stent
Study NCT01263314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8266
Description: Oral capsules, 0.1 mg potency
Study NCT04146311 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hypertonic saline
Description: A bolus injection (0.25 ml) of hypertonic saline (5%) into the left infrapatellar fat pad.
Study NCT01263314 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo capsules to match MK-8266 capsules
Study NCT02752724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine anesthesia for ECT index course with measurement cerebral metabolic regional oximetry, EEG seizure quality, cognitive scoring and serum metabolites.
Study NCT04146311 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: isotonic saline
Description: A bolus injection (0.25 ml) of isotonic saline (5%) into the left infrapatellar fat pad.
Study NCT04146311 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Motor training
Description: All the subjects recruited need to have a short-term motor task training at home. 30 times a session, totally 2 sessions a day for 6 days
Study NCT04146311 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Motor training
Description: All the subjects recruited need to have a short-term motor task training at home. 30 times a session, totally 2 sessions a day for 6 days
Study NCT04146311 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor training
Description: All the subjects recruited need to have a short-term motor task training at home. 30 times a session, totally 2 sessions a day for 6 days
Study NCT00586222 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo pill of the same size, color, and shape as the dietary supplement.
Study NCT04597684 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cementless Total Knee Arthroplasty
Description: Total Knee Arthroplasty (TKA) with cementless knees
Study NCT02752724 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methohexital
Description: Methohexital anesthesia for ECT index course with measurement cerebral metabolic regional oximetry, EEG seizure quality, cognitive scoring and serum metabolites.
Study NCT00545480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibandronate [Bonviva/Boniva]
Description: 150mg po monthly for 12 months (with feedback)
Study NCT00545480 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ibandronate [Bonviva/Boniva]
Description: 150mg po monthly for 12 months (without feedback)
Study NCT04211844 — intervention group
Intervention type: DRUG
Intervention: sofosbuvir plus daclatasvir
Description: 50 patients in the first group will receive 400 mg sofosbuvir plus daclatasvir 60 mg once daily for 12 weeks.
Study NCT03275766 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DLPFC facilitatory
Description: 15 Hz stimulation of left dorsolateral prefrontal cortex (DLPFC)(15 sessions/3weeks, 1500 stimuli per session, stimulation intensity 100% of the individual active motor threshold; in total 22500 stimuli
Study NCT03275766 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMA inhibitory
Description: 1 Hz stimulation of preSMA/SMA (15 sessions/3weeks, 1500 stimuli per session, stimulation intensity 100% of the individual active motor threshold; in total 22500 stimuli
Study NCT03275766 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMA facilitatory
Description: Three pulses of stimulation at 50 Hz of preSMA/SMA, repeated every 200 ms. 2 s trains are repeated every 10 s for a total of 190 s (600 pulses, 200 seconds). intensity 80% of individual active motor threshold; in total 9000 stimuli
Study NCT03275766 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham TMS
Description: Determination of active motor threshold and subsequent stimulation with the placebo coil, with the same sounds but without effects. 15 sessions in three weeks, duration of 20 mins per session
Study NCT06156735 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Passive Music Therapy (P)
Description: Music Therapy Intervention
Study NCT06156735 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Music Therapy (A)
Description: Music Therapy Intervention
Study NCT06156735 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care Control Condition (C)
Description: Without any intervention
Study NCT04229524 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fluorescence angiography
Description: After the tube and stomach were made during surgery, the predetermined anastomosis position was marked with sutures in advance according to the doctor's experience, and then 0.04ml / kg indocyanine green injection was injected into the central vein. Next, dynamic observation and recording of the tube-gastric anastomosis area in 136 seconds using a fluorescent imaging system with a fixed focal length till the fluorescence reaching range and intensity. If the average value of the fluorescence value of the anastomosis position is greater than 30, then the anastomosis position may be according to the original plan or moved to the proximal part. If the average fluorescence value of the predetermined anastomosis position is less than 30, the anastomosis must move to proximal part ensure anastomosis with fluorescence value at least> 30.